1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,123 | 0,144 | 02.06. | |
| 0,000 | 0,000 | 02.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 14.05. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT PRESENTATION OF PRECLINICAL STUDIES OF ANTI-CGC ANTIBODY (HC2) AT SID ANNUAL MEETING 2026 | 5 | HKEx | ||
| 13.05. | SinoMab BioScience Limited: Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK | 476 | JCN Newswire | HONG KONG, May 13, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce that Dr. Shui... ► Artikel lesen | |
| 27.04. | SINOMAB BIO-B (03681): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 2 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTICE OF 2026 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD AT ROOM 3, 14/F, FAIRMONT HOUSE, 8 COTTON TREE DRIVE, CENTRAL, HONG KONG ... | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED ELECTION OF A DIRECTOR AND PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK ... | - | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 01.04. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF SM17 FOR ATOPIC DERMATITIS IN CHINA | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): RESIGNATION OF NON-EXECUTIVE DIRECTORS | - | HKEx | ||
| 25.03. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT TOPLINE RESULTS FROM PHASE 1 BRIDGING STUDY FOR ROUTE OF ADMINISTRATION CONVERSION OF SM17 IN CHINA | - | HKEx | ||
| 24.03. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | - | HKEx | ||
| 24.03. | SinoMab BioScience Limited: SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement | 390 | JCN Newswire | HONG KONG, Mar 24, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce its annual... ► Artikel lesen | |
| 23.03. | SINOMAB BIO-B (03681): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025; AND CHANGE IN USE OF PROCEEDS | 2 | HKEx | ||
| 12.03. | SINOMAB BIO-B (03681): CONNECTED TRANSACTION - TERMINATION OF LEASE AGREEMENT | - | HKEx | ||
| 10.03. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | - | HKEx | ||
| 24.02. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR IBD OF SM17 BY NMPA | - | HKEx | ||
| 18.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 18.02.2026 | 1.508 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2026
Aktien
1 US02083X2027 Alpine Income Property... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 258,08 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,480 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,71 | 0,00 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,690 | -0,06 % | Relay Therapeutics Shares Jump 18% | ||
| COGENT BIOSCIENCES | 32,760 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| QIAGEN | 30,705 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,300 | +0,13 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,505 | +0,02 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 10,690 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DISC MEDICINE | 68,00 | 0,00 % | Disc Medicine launches expanded access program for bitopertin | ||
| FULCRUM THERAPEUTICS | 3,140 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | ? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik- (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,615 | +0,14 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| MINERALYS THERAPEUTICS | 28,850 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection ... | - Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease - - In participants... ► Artikel lesen | |
| CG ONCOLOGY | 55,47 | -0,11 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen |
Das Unternehmen SINOMAB BIOSCIENCE LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+0,81 %) liegt der Kurs bei 0,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.